Small-molecule inhibitors of protein-protein interactions

Z. Liu, H. Chen, E. A. Wold, J. Zhou

Research output: Chapter in Book/Report/Conference proceedingChapter

11 Scopus citations


Targeting protein-protein interactions (PPIs) for therapeutic development was once considered undruggable due to the large and flat interactive surfaces that lack cavities. Facilitated by the development of new concepts, such as hotspots, screening techniques, and computational tools, various small molecules modulating PPIs have been achieved with a number of them having progressed into different phases of clinical trials and a portion recently reaching the market. In this article, we discuss the critical role of PPIs associated with various human diseases and different approaches to the identification of small molecular inhibitors targeting PPIs. We also highlight recent advances in developing such modulators as novel therapeutics.

Original languageEnglish (US)
Title of host publicationDrug Discovery Technologies
PublisherElsevier Inc.
Number of pages25
ISBN (Electronic)9780128032008
ISBN (Print)9780128032015
StatePublished - Jun 3 2017


  • Allosteric sites
  • CNS disorders
  • Cancer therapy
  • Drug development
  • Drug discovery
  • Drug target
  • Fragment-based drug design
  • High-throughput screening
  • Hotspots
  • Inflammation
  • Interactive surface
  • Peptidomimetics
  • Protein-protein interaction inhibitors
  • Protein-protein interactions
  • Virtual screening

ASJC Scopus subject areas

  • General Chemistry


Dive into the research topics of 'Small-molecule inhibitors of protein-protein interactions'. Together they form a unique fingerprint.

Cite this